Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
02 mai 2024 09h05 HE
|
Kriya Therapeutics, Inc.
– Kriya is developing KRIYA-825 as a potential one-time gene therapy expressing a fusion protein inhibiting the activity of complement C3 and C5 for the treatment of Geographic Atrophy – PALO...
Kriya Announces Six Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024
22 avr. 2024 16h30 HE
|
Kriya Therapeutics, Inc.
– Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic disease and neurology – – Company to host symposium on “Advancing Gene...
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
08 janv. 2024 09h00 HE
|
Kriya Therapeutics, Inc.
– Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
05 janv. 2024 09h00 HE
|
Kriya Therapeutics, Inc.
– KRIYA-586 is designed to be a one-time treatment delivered by focal peribulbar injection, that encodes an antibody blocking the Insulin-Like Growth Factor 1 Receptor (IGF-1R), a clinically validated...
Kriya to Present at the J.P. Morgan 42nd Annual Healthcare Conference
20 déc. 2023 08h30 HE
|
Kriya Therapeutics, Inc.
PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common...
Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy
27 sept. 2023 08h30 HE
|
Kriya Therapeutics, Inc.
– Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for multiple ophthalmology gene therapy product candidates – ...
Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases
06 sept. 2023 08h30 HE
|
Kriya Therapeutics, Inc.
– Kriya envisions treating people with NASH using a one-time intramuscular gene therapy enabling continuous expression of native FGF21 – – Kriya anticipates advancing its NASH gene therapy candidate...
Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases
26 juil. 2023 08h25 HE
|
Kriya Therapeutics, Inc.
– Kriya's therapeutic pipeline addresses a broad range of diseases that collectively affect millions of patients worldwide—with a goal of delivering transformational clinical benefits with one-time...